Dr Neil Gross: Cemiplimab Has Great Potential in cSCC | AJMC
Dr Neil Gross: Cemiplimab Has Great Potential in cSCC | AJMC
2022年12月5日
ajmc.com
C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
1:45
C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
已浏览 293 次11 个月之前
YouTubeVJOncology
Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2:05
Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
7 个月之前
targetedonc.com
CSCC Treatment Options: Cemiplimab and Pembrolizumab | OncLive
CSCC Treatment Options: Cemiplimab and Pembrolizumab | OncLive
2023年4月19日
onclive.com
Dr. Rischin on the FDA Approval of Cemiplimab for CSCC
0:37
Dr. Rischin on the FDA Approval of Cemiplimab for CSCC
已浏览 137 次2018年9月28日
YouTubeOncLive
U.S. Food and Drug Administration - FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma (YouTube)
6:30
U.S. Food and Drug Administration - FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma (YouTube)
已浏览 44 次2025年4月22日
Internet ArchiveGrumpy Systems
Regeneron Pharmaceuticals, Inc.: Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery ...
Regeneron Pharmaceuticals, Inc.: Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery ...
6 个月之前
finanznachrichten.de
4:27
Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma
已浏览 150 次8 个月之前
YouTubeecancer
3:40
Adjuvant cemiplimab in high-risk CSCC: a turning point between present and future
已浏览 4 次4 个月之前
YouTubeOncoInfoTV
Dr. Rischin Discusses Cemiplimab in Cervical Cancer | OncLive
2018年10月25日
onclive.com
The Role of Continuing Cemiplimab in Second-Line Therapy After Progression | Managed Healthcare Executive
2025年4月18日
managedhealthcareexecutive.com
1:37
Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCC
已浏览 133 次2020年8月20日
YouTubeOncLive
4:17
Real-World Management of Patients on Cemiplimab
已浏览 758 次2019年6月11日
YouTubeTargeted Oncology
0:33
Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma
已浏览 1854 次2018年9月28日
YouTubeOncLive
6:45
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma
已浏览 260 次2021年8月24日
YouTubeBMJ Group
1:18
Neoadjuvant cemiplimab in patients with stage II-IV cutaneous squamous cell carcinoma
已浏览 1319 次2022年9月13日
YouTubeVJOncology
1:42
Marina Chiara Garassino, MD presents 5-year results from the EMPOWER-Lung 1 trial, discussing cemiplimab monotherapy's long-term survival benefits in advanced #NSCLC https://www.onclive.com/view/cemiplimab-monotherapy-for-first-line-advanced-nsclc-patients-with-pd-l1-expression-50-5-y-outcomes-of-empower-lung | OncLive
已浏览 37 次2025年1月24日
FacebookOncLive
4:13
Cemiplimab in Managing Advanced cSCC
已浏览 940 次2019年6月4日
YouTubeTargeted Oncology
7:51
Carcinoma squamocellulare avanzato, conferme di efficacia per l’immunoterapia con cemiplimab
已浏览 2367 次2020年6月3日
YouTubePharmaStarTV
1:16
🚨 Big news for high-risk skin cancer patients!The FDA just approved Cemiplimab (Libtayo)
已浏览 1万 次6 个月之前
YouTubeDr. Dustin Portela
Dr. Dustin Portela | Skincare & Health Expert | 🚨 Big news for high-risk skin cancer patients! The FDA just approved Cemiplimab (Libtayo) for use before metastasis in patients with... | Instagram
已浏览 1.7万 次6 个月之前
Instagramdrdustinportela
1:28
Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell Carcinoma
已浏览 1472 次2018年6月7日
YouTubeOncLive
What Is Immunotherapy? | Cancer Research Institute
8 个月之前
cancerresearch.org
0:52
Benefit With Cemiplimab in Patients With mCSCC
已浏览 491 次2018年12月13日
YouTubeTargeted Oncology
1:04
Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC
已浏览 523 次2020年8月7日
YouTubeOncLive
NICE recommends pembrolizumab for 1,600 more people with breast cancer - Cancer Research UK - Cancer News
2022年11月14日
cancerresearchuk.org
4:51
Advanced CSCC: The New Systemic Therapy
已浏览 529 次2018年10月31日
YouTubeTargeted Oncology
5:48
The Impact of Systemic Therapy and KEYNOTE-048 Trial
已浏览 148 次2019年2月25日
YouTubeOncLive
FDA Approves Dostarlimab Plus Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer | OncLive
2023年7月31日
onclive.com
3:07
Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC
已浏览 255 次2024年6月28日
YouTubeOncLive
展开